Navigation Links
EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
Date:5/29/2013

A further report on the results of EORTC trial 26951 indicates that CpG island methylator phenotype (CIMP) status and O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation as assessed by MGMT-STP27 are the most informative for identifying grade III glioma patients who might benefit from the addition of procarbazine, CCNU and vincristine (PCV) chemotherapy to radiation therapy. Prior results had shown that PCV chemotherapy following standard radiation therapy delayed tumor growth and extended the lives of patients with anaplastic oligodendroglial tumors, a hard-to-treat form of brain cancer.

Results observed in the phase III RTOG 9402 trial, in this case with chemotherapy preceding radiation therapy, complemented the results obtained previously in the EORTC 26951 trial and found that administering both PCV and radiation therapy led to comparable improvements in survival for oligodendroglial tumor patients with specific deletions of genetic material in chromosomes 1p and 19q, but not for patients without the mutation.

Nevertheless up to 30% of oligodendroglial tumors do not have 1p/19q deletion but may still respond to chemotherapy. Analyses of EORTC 26951 and RTOG 9402 suggested that other molecularly defined subsets of grade III tumors might benefit as well.

The new results will be presented at an ASCO 2013 Clinical Science Symposia on Sunday, 02 June 2013 by Dr. Martin J. Van Den Bent of the Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands, and coordinator of the study. According to Dr. Van Den Bent, "This is further evidence pointing towards a central role of methylation in the behavior of IDH (isocitrate dehydrogenase) mutated glioma and, more in general, of the MGMT gene function in glioma when treated with chemotherapy."

Methylation profiles of 115 patients were conducted using Infinium HumanMethylation27 or Infinium HumanMethylation450 BeadChip kits. (Validation in an independent dataset is required.)

In these analyses, two markers, CIMP and MGMT-STP27 methylation status, were considered promising in being able to differentiate between patients who will and will not respond to PCV chemotherapy. Two other markers, IDH mutation status and 1p/19 chromosomal deletion, had less strength in achieving this differentiation.

The EORTC 26951 intergroup trial was coordinated by the EORTC Brain Tumor Group in collaboration with the Medical Research Council Clinical Trial Unit and supported by Stichting STOPhersentumor.nl. This academic trial was activated in August 1996, closed in March 2002, and included 368 patients in 40 sites in 10 countries: Austria, Belgium, Finland, France, Germany, Hungary, Italy, Sweden, The Netherlands, and the United Kingdom.


'/>"/>

Contact: John Bean
john.bean@eortc.be
32-277-41671
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
2. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
3. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Offer New Guided Weight Loss Tips Now Found in New Study to Help Patients Lose Weight Fast
4. A Strong Marriage Can Shield Kids From Dads Depression: Study
5. Narconon Releases Early Study of Delaware Prison Program, Demonstrating Crime Reduction Consistent with More Recent Narconon Results
6. Changing gut bacteria through diet affects brain function, UCLA study shows
7. GOJO presents electronic hand hygiene compliance study at APIC conference
8. Alzheimers Patients Mimic Emotions of Those Around Them: Study
9. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
10. Kids Poisoned by Medical Marijuana, Study Finds
11. Involving Patients in Decisions Raises Health Care Costs, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze ... industry, announces Chris Brandl as its New Guest Director. , Brandl is ... corporations throughout his career. He began his professional career at Omnium Worldwide, now ...
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been ... women who become dependent on opioid painkillers has fallen short. From 1999 until 2010, ... a 237% increase in fatal overdoses in male populations.(1) , The proportion of women ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, ... inflammatory gum condition that occurs when the bacteria in plaque infect the gums and ... as a scaling and root planing or SRP, and can include surgical therapies if ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... RGN-137, GtreeBNT Co., Ltd., received a positive response ... clinical trial design for RGN-137 to treat epidermolysis ... gel that incorporates Thymosin beta 4 ("Tß4") as ...
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... (PII) celebrates the pharmaceutical companies that are most successful at ... ... question: if you gave the same molecule to two different ... it? Based on systematic, objective analysis of each ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies ... grow at a CAGR of 8.9% from 2016-2021 and CAGR of ... CAGR of 9.1% from 2016 to 2027. The market is estimated ... ... Read on to discover how you can exploit the future ...
Breaking Medicine Technology: